Eculizumab, a real-life successful treatment for refractory cold agglutinin-mediated auto-immune hemolytic anemia secondary to lymphoproliferative disorders

Ann Hematol. 2021 Aug;100(8):2105-2106. doi: 10.1007/s00277-021-04557-1. Epub 2021 May 18.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Anemia, Hemolytic, Autoimmune / complications*
  • Anemia, Hemolytic, Autoimmune / drug therapy*
  • Anemia, Hemolytic, Autoimmune / immunology
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Complement Inactivating Agents / therapeutic use*
  • Cryoglobulins / immunology
  • Humans
  • Lymphoproliferative Disorders / complications*
  • Lymphoproliferative Disorders / immunology
  • Male

Substances

  • Antibodies, Monoclonal, Humanized
  • Complement Inactivating Agents
  • Cryoglobulins
  • cold agglutinins
  • eculizumab